KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Inventory (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 15 years of Inventory data on record, last reported at $1.7 billion in Q4 2025.

  • For Q4 2025, Inventory rose 39.94% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, up 39.94%, while the annual FY2025 figure was $1.7 billion, 39.94% up from the prior year.
  • Inventory reached $1.7 billion in Q4 2025 per VRTX's latest filing, up from $1.6 billion in the prior quarter.
  • Across five years, Inventory topped out at $1.7 billion in Q4 2025 and bottomed at $298.9 million in Q1 2021.
  • Average Inventory over 5 years is $780.7 million, with a median of $646.1 million recorded in 2023.
  • Peak YoY movement for Inventory: grew 13.4% in 2022, then soared 77.41% in 2023.
  • A 5-year view of Inventory shows it stood at $353.1 million in 2021, then skyrocketed by 30.44% to $460.6 million in 2022, then surged by 60.4% to $738.8 million in 2023, then soared by 63.16% to $1.2 billion in 2024, then skyrocketed by 39.94% to $1.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $1.7 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.5 billion in Q2 2025.